Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01834651 | A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases | completed | Phase 2 | 17 | Edwin Posadas, MDOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00078585 | PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | completed | Phase 2 | 120 | Bavarian NordicINDUSTRY | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00585962 | Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate | completed | Phase 2 | 57 | Massachusetts General HospitalOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00678054 | Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA) | completed | Phase 2 | 30 | University of California, San FranciscoOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT00251225 | A Study of Imatinib and Docetaxel in Prostate Cancer | completed | Phase 2 | 49 | Leonard ApplemanOTHER | 1 | Aug 9, 2017 | clinicaltrials |
| NCT00551525 | Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 67 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 25, 2017 | clinicaltrials |
| NCT00005096 | Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00924313 | Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00005916 | PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00246753 | Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy(NRR) | completed | Phase 2 | 29 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01023061 | Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer(RAD1) | completed | Phase 2 | 24 | University of WashingtonOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00225420 | Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer(NRR) | completed | Phase 1 / Phase 2 | 23 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT01431391 | Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | completed | Phase 2 | 68 | DendreonINDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT00658697 | Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer | completed | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00486642 | Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 24, 2017 | clinicaltrials |
| NCT02105675 | Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 60 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02107391 | Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer | completed | Phase 2 | 63 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02107404 | Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer | completed | Phase 2 | 150 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02137746 | Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer | completed | Phase 2 | 24 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT00715078 | To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen | completed | Phase 2 | 122 | DendreonINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00901342 | Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer | completed | Phase 2 | 104 | DendreonINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00170157 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 112 | Mayo ClinicOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02022371 | Prostate Cancer Genomic Heterogeneity(PROGENY) | completed | Phase 1 / Phase 2 | 50 | University College London HospitalsOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00182741 | Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00003781 | Docetaxel in Treating Patients With Stage IV Prostate Cancer | completed | Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00004043 | Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer | completed | Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00017563 | Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 57 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00017576 | Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01228084 | Sulforaphane in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02212197 | Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer | completed | Phase 2 | 51 | Camurus ABINDUSTRY | 2 | Apr 25, 2017 | clinicaltrials |
| NCT00669656 | Herbal Therapy for Treatment of Recurrent Prostate Cancer | completed | Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00118092 | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02135445 | Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer | completed | Phase 2 | 103 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 13, 2017 | clinicaltrials |
| NCT00574769 | Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02440308 | 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00895310 | Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy | completed | Phase 2 | 30 | University of California, DavisOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00769795 | Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer | completed | Phase 2 | 29 | University of WashingtonOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT01695044 | A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) | completed | Phase 2 | 119 | Progenics Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2017 | clinicaltrials |
| NCT02020135 | An Open-label Extension Study of PSMA ADC 2301 in mCRPC | completed | Phase 2 | 9 | Progenics Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2017 | clinicaltrials |
| NCT00957905 | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01620515 | Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer | completed | Phase 2 | 141 | Nymox CorporationINDUSTRY | 1 | Mar 10, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2017source: clinicaltrials